Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics

Documenti analoghi

• Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
  di: Wei Yin, et al.
  Pubblicazione: (2024)
• Probe substrates assay estimates the effect of polyphyllin H on the activity of cytochrome P450 enzymes in human liver microsomes
  di: Erhao Wang, et al.
  Pubblicazione: (2024)
• Risk of Major Congenital Malformations Associated With the First‐Trimester Exposure to Antipsychotics: A Large Claims Database Study
  di: Ryo Obara, et al.
  Pubblicazione: (2026)
• The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
  di: Vanessa Martins, et al.
  Pubblicazione: (2024)
• Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients
  di: Ridhi Parasrampuria, et al.
  Pubblicazione: (2025)